Dyslipidemia is a major risk factor for cardiovascular events, cardiovascular mortality, and all-cause mortality. The earlier in life dyslipidemia is treated, the better the prognosis. The current book is an excellent one on dyslipidemia written by experts on this topic. This book includes 12 chapters including 5 on lipids, 4 on hypercholesterolemia in children, and 3 on the treatment of dyslipidemia. This book should be read by all health care professionals taking care of patients, including pediatricians since atherosclerotic cardiovascular disease begins in childhood.

The present book contains the Proceedings of a two day Symposium on Uremic Toxins organized at the University of Ghent in Belgium. A series of guest lectures, free communications and posters have been presented. An international audience of 163 scientists from 16 nationalities listened to and discussed extensively a spectrum of topics brought forward by colleagues and researchers who worked for many years in the field of Uremic Toxins. There is a striking contrast between all the new dialysis strategies available in the work to "clean" the uremic patients and the almost non-progression of our knowledge on uremic toxins in the past decade. In this sense the symposium was felt by all participants as a new start for the research in the biochemical field of the definition of uremia. If the present volume would stimulate new work in this field in order to define uremia, or identify the uremic toxins, the purpose of the organizers would be maximally fulfilled.

This comprehensive book examines the complex interplay between endocrine and kidney disorders, and how this inter-relationship impacts patients with chronic kidney disease. Authored by experts in areas of endocrinology and nephrology, chapters cover a variety of topics, including diabetes, metabolic syndrome, thyroid dysfunction, gonadal disorders, dyslipidemia, mineral bone disorders, obesity, and pituitary disorders. These comorbidities are thoroughly examined and provide the clinician, researcher, and trainee with a greater understanding of the impact of endocrine disorders on kidney disease patients, the ability to identify persistent gaps in knowledge for future investigation, and move closer towards the goal of improving the health and survival of the chronic kidney disease population.

This timely, concise title provides an important update on clinical lipid management. Using information from recent clinical trials and in special populations, the book begins by offering an easy-to-read overview of LDL, HDL, and triglyceride metabolism and the genetics of lipid disorders. The link between inflammation and lipids, and how this relates to atherosclerosis development, is also addressed, as are the measures of subclinical atherosclerosis in patients with abnormal lipid levels. Lipid abnormalities in children, with a particular focus on vulnerable populations (with an emphasis on ethnicity and childhood obesity), are covered. The treatment goals and approaches for managing lipids in the clinic are thoroughly discussed, emphasizing the important role of statin use and addressing controversies of lipid management in special populations such as heart failure, end stage kidney disease and fatty liver disease. Of special note, an important update on how new HIV medications impact lipid levels is provided. In all, Lipid Management: From Basics to Clinic, is an invaluable, handy resource for understanding changes in lipids in different populations and for sharpening the clinical approach to managing complicated lipid cases.

Dyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children. Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists. For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Program’s Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia. Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewed and represent a comprehensive assessment of the field. A major addition to the literature, Dyslipidemias: Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias.